Sandoz is to appeal a court decision preventing it from launching a cheaper biosimilar competitor to Amgen’s Enbrel (etanercept) inflammatory diseases drug in the US, three years after approval by the ...

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated Company aims ...

THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel ® ...

The Biden administration has released the first 10 drugs subject to price negotiation with Medicare under the Inflation Reduction Act (IRA), and among those chosen were Stelara (ustekinumab) and ...

SAN FRANCISCO, November 11, 2001– Data from a Phase 2 clinical study of ENBREL® (etanercept) in ankylosing spondylitis will be presented this week at the 65th Annual Scientific Meeting of the American ...

DENVER — Colorado's first-in-the-nation law that allows a state board to limit prescription drug prices is facing a new legal challenge. The pharmaceutical company Amgen is suing the Colorado ...

Amgen’s Enbrel (etanercept), a blockbuster biologic treatment for a number of autoimmune diseases, including rheumatoid arthritis and psoriasis, has been an attractive target for biosimilar makers.

SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...

On September 30, the U.S. District Court for the Eastern District of Virginia granted in part and denied in part the Motion to Dismiss filed by Amgen, Inc. and Immunex Corporation (“Amgen”) in a class ...